The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients

Pharmacogenetics

Volumn 10, Issue 4, 2000, Pages 335-341

  Suzuki, Akihito ^a   Mihara, Kazuo ^a   Kondo, Tsuyoshi ^a   Tanaka, Osamu ^a   Nagashima, Udai ^a   Otani, Koichi ^b   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Nemonapride; Schizophrenia; Taq1 A DRD2 polymorphism; Therapeutic response

Indexed keywords

DNA; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; EMILACE; EMONAPRIDE; RESTRICTION ENDONUCLEASE; BENZAMIDE DERIVATIVE; NEUROLEPTIC AGENT; TAQ POLYMERASE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG RESPONSE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RATING SCALE; RECEPTOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; ADULT; BLOOD; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; DOPAMINE ANTAGONISTS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TAQ POLYMERASE;

EID: 0033623809     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200006000-00007     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. edn. Washington DC: American Psychiatric Association; 1987.
2. Arranz MJ, Li T, Munro J, Liu X, Murray R, Collier DA, Kerwin RW. Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics 1998; 8:481-484.
3. 1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. Eur J Pharmacol 1997; 334:141-147.
4. 2 receptor locus. Biol Psychiatry 1993: 34:204-209.
5. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiat Scand 1986: 73 (Suppl 326):1S-37S.
6. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJH, Comings DE. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 1995; 5:121-141.
7. Bohm C, Placchi M, Stallone F, Gammans RE, Alms DR, Shrotriya RC, Robinson DS. A double-blind comparison of buspirone, clobazam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 1990; 10 (Suppl 3):38S-42S.
8. 2 dopamine receptors is associated with the Type I Syndrome. In: Riederer P, Usdin E, editors. Transmitter biochemistry of human brain tissue. London: McMillan; 1981, pp. 85-96.
9. Dahl SG. Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 1986; 11:36-61.
10. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486.
11. Fitton A, Heel RC. Clozapine. Drugs 1990; 40:722-747.
12. 2 receptor gene is located on chromosome 11 at q22-q23 and identifies a Taq1 RFLP. Am J Hum Genet 1989a; 45:778-785.
13. 2 dopamine receptor. Proc Natl Acad Sci USA 1989b; 86:9762-9766.
14. Grandy DK, Zhang Y, Civelli O. PCR detection of the Taq1A RFLP at the DRD2 locus. Hum Mol Genet 1993; 2:2197.
15. Hansen LB, Larsen NE, Gulmann N. Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology 1982; 78:112-115.
16. 2 dopamine receptor expression. Mol Psychiatry 1998; 3:198-203.
17. Kondo T, Otani K, Ishida M, Mihara K, Tanaka O, Kaneko S, Fukushima Y. A study of the therapeutic spectrum of a fixed-dose of zotepine and its relationship with serum concentrations of the drug. Hum Psychopharmacol 1993; 8:133-139.
18. 2 receptor gene. Mol Psychiatry 1998; 3:261-265.
19. Lindenmayer J-P, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology 1995; 28:22-31.
20. Lydiard RB, Laird LK. Prediction of response to antipsychotics. J Clin Psychopharmacol 1988; 8:3-13.
21. Nagasaki T, Ohkubo T, Sugawara K, Yasui N, Ohtani K, Kaneko S. High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. J Chromatogr B 1998; 714:293-298.
22. 2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 1998; 16:33-45.
23. Otani K, Kondo T, Yasui N, Suzuki A, Furukori H, Kaneko S, et al. Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients. Hum Psychopharmacol 1997; 12:591-594.
24. 2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3:256-260.
25. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990; 10 (Suppl 3):67S-76S.
26. Satoh K, Someya T, Shibasaki M. Effects of nemonapride on positive and negative symptoms of schizophrenia. Int Clin Psychopharmacol 1996; 11:279-281.
27. Schotte A, Bonaventure P, Janssen PFM, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotic hitherto used. Jpn J Pharmacol 1995; 69:399-412.
28. 3 receptor: basic and clinical aspects. Clin Neuropharmacol 1993; 16:295-314.
29. Seeman P. Dopamine receptors. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology. 4th edn. New York: Raven Press; 1995. pp. 295-302.
30. Shaikh S, Collier D, Arranz M, Ball D, Gill M, Kerwin R. DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 1994; 343:1045-1046.
31. 3) as a target for neuroleptics. Nature 1990; 347:146-151.
32. 3H]raclopride for dopamine D-2 receptor binding to rat striatum. Eur J Pharmacol 1989; 173:177-182.
33. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7:479-484.
34. Van Putten T, Marder SR, Mintz J. Poland RE. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992; 149:500-505.
35. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610-614.
36. Volavka J, Cooper T, Czobor P, Bitter I, Meisner M, Laska E, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49:354-361.
37. Wieselgren IM, Lindström LH. A prospective 1-5 year outcome study in first-admitted and readmitted schizophrenic patients: relationship to heredity, premorbid adjustment, duration of disease and education level at index admission and neuroleptic treatment. Acta Psychiatr Scand 1996; 93:9-19.